Scholarlink

<p>Protein biomarkers from plasma extracellular vesicles (EVs) have been extensively identified in various diseases. To explore biomarkers associated with diabetic retinopathy (DR) progression, we designed two cohorts, discovery and validation cohorts, including four groups: healthy control, type 2 diabetes mellitus, non-proliferative DR (NPDR), and proliferative DR (PDR). A total of 32 differentially expressed proteins (DEPs) were screened by proteomic analysis in the four groups of the discovery cohort. Among them, four hub proteins, CELA3A, CELA3B, GLUD1, and CTRC, were identified to be related to DR progression, and their correlation with clinical characteristics was further analyzed. Subsequently, enzyme-linked immunosorbent assay in the validation cohort confirmed that the expression levels of CELA3A, CELA3B, and CTRC were consistent with the proteomic results. Receiver operator characteristic curve analysis found that the AUC values of three hub proteins and their composed panels distinguishing NPDR/PDR from DM were all &gt; 0.7, except for DM-NPDR of CELA3B. In addition, CELA3A, CELA3B, and CTRC proteins were significantly correlated with some clinical indicators of DR. This study indicates that the plasma EV proteins CELA3A, CELA3B, and CTRC are expected to become biomarkers to monitor DR progression and provide guidance for DR diagnosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of plasma extracellular vesicle protein biomarkers in diabetic retinopathy progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月9日

查看全文
  • Zhen Li,
  • Xiaojing Pang,
  • Hang Wu,
  • Junyuan Zhang,
  • Zhili Wang

摘要

Protein biomarkers from plasma extracellular vesicles (EVs) have been extensively identified in various diseases. To explore biomarkers associated with diabetic retinopathy (DR) progression, we designed two cohorts, discovery and validation cohorts, including four groups: healthy control, type 2 diabetes mellitus, non-proliferative DR (NPDR), and proliferative DR (PDR). A total of 32 differentially expressed proteins (DEPs) were screened by proteomic analysis in the four groups of the discovery cohort. Among them, four hub proteins, CELA3A, CELA3B, GLUD1, and CTRC, were identified to be related to DR progression, and their correlation with clinical characteristics was further analyzed. Subsequently, enzyme-linked immunosorbent assay in the validation cohort confirmed that the expression levels of CELA3A, CELA3B, and CTRC were consistent with the proteomic results. Receiver operator characteristic curve analysis found that the AUC values of three hub proteins and their composed panels distinguishing NPDR/PDR from DM were all > 0.7, except for DM-NPDR of CELA3B. In addition, CELA3A, CELA3B, and CTRC proteins were significantly correlated with some clinical indicators of DR. This study indicates that the plasma EV proteins CELA3A, CELA3B, and CTRC are expected to become biomarkers to monitor DR progression and provide guidance for DR diagnosis.